See also: Generic Nucynta
Nucynta ER is a brand name of tapentadol, approved by the FDA in the following formulation(s):
NUCYNTA ER (tapentadol hydrochloride - tablet, extended release; oral)
Manufacturer: JANSSEN PHARMS
Approval date: August 25, 2011
Strength(s): EQ 100MG BASE, EQ 150MG BASE, EQ 200MG BASE, EQ 250MG BASE [RLD], EQ 50MG BASE
Has a generic version of Nucynta ER been approved?
No. There is currently no therapeutically equivalent version of Nucynta ER available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nucynta ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Patent 6,071,970
Issued: June 6, 2000
Inventor(s): Mueller; Alan L. & Balandrin; Manuel F. & VanWagenen; Bradford C. & DelMar; Eric G. & Moe; Scott T. & Artman; Linda D. & Barmore; Robert M.
Assignee(s): NPS Pharmaceuticals, Inc.
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).Patent expiration dates:
- June 6, 2017✓
- June 6, 2017
Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Patent 7,994,364
Issued: August 9, 2011
Inventor(s): Fischer; Andreas & Buschmann; Helmut & Gruss; Michael & Lischke; Dagmar
Assignee(s): Gruenenthal GmbH
A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.Patent expiration dates:
- June 27, 2025✓✓✓
- June 27, 2025
Abuse-proofed dosage form
Patent 8,075,872
Issued: December 13, 2011
Inventor(s): Arkenau-Maric; Elisabeth & Bartholomäus; Johannes & Kugelmann; Heinrich
Assignee(s): Gruenenthal GmbH
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.Patent expiration dates:
- November 20, 2023✓
- November 20, 2023
1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Patent RE39593
Issued: April 24, 2007
Inventor(s): Buschmann; Helmut & Strassburger; Wolfgang & Friderichs; Elmar
Assignee(s): Gruenenthal GmbH
1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.Patent expiration dates:
- August 5, 2022✓✓✓
- August 5, 2022
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- November 20, 2013 - NEW CHEMICAL ENTITY
- August 25, 2014 - NEW DOSAGE FORM
See also...
- Nucynta ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Nucynta ER Consumer Information (Cerner Multum)
- Nucynta ER Advanced Consumer Information (Micromedex)
- Tapentadol Consumer Information (Drugs.com)
- Tapentadol Consumer Information (Wolters Kluwer)
- Tapentadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Tapentadol Consumer Information (Cerner Multum)
- Tapentadol Advanced Consumer Information (Micromedex)
- Tapentadol Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment